Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-268045
Filing Date
2025-11-06
Accepted
2025-11-06 07:05:06
Documents
85
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q glue-20250930.htm   iXBRL 10-Q 2684857
2 EX-10.1 glue-ex10_1.htm EX-10.1 1408905
3 EX-31.1 glue-ex31_1.htm EX-31.1 19248
4 EX-32.1 glue-ex32_1.htm EX-32.1 11771
  Complete submission text file 0001193125-25-268045.txt   12247925

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20250930.xsd EX-101.SCH 1258766
87 EXTRACTED XBRL INSTANCE DOCUMENT glue-20250930_htm.xml XML 2183787
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 251456093
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)